Maa: Yhdysvallat
Kieli: englanti
Lähde: NLM (National Library of Medicine)
METHOHEXITAL SODIUM (UNII: 60200PNZ7Q) (METHOHEXITAL - UNII:E5B8ND5IPE)
Par Pharmaceutical, Inc.
METHOHEXITAL SODIUM
METHOHEXITAL SODIUM 500 mg
INTRAMUSCULAR
PRESCRIPTION DRUG
BREVITAL can be used in adults as follows: - 1.For intravenous induction of anesthesia prior to the use of other general anesthetic agents. - 2.For intravenous induction of anesthesia and as an adjunct to subpotent inhalational anesthetic agents (such as nitrous oxide in oxygen) for short surgical procedures; BREVITAL may be given by infusion or intermittent injection. - 3.For use along with other parenteral agents, usually narcotic analgesics, to supplement subpotent inhalational anesthetic agents (such as nitrous oxide in oxygen) for longer surgical procedures. - 4.As intravenous anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli (see WARNINGS ). - 5.As an agent for inducing a hypnotic state. BREVITAL can be used in pediatric patients older than 1 month as follows: - 1.For rectal or intramuscular induction of anesthesia prior to the use of other general anesthetic agents. - 2.For rectal or intramuscular induction of anesthesia and as an adjun
Store between 20° to 25°C (68° to 77°F). (See USP Controlled Room Temperature.) BREVITAL® Vials*: The 500 mg vials (with 30 mg anhydrous sodium carbonate) are available as follows: *In crystalline form.
New Drug Application
BREVITAL SODIUM- METHOHEXITAL SODIUM INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION PAR PHARMACEUTICAL, INC. ---------- BREVITAL (METHOHEXITAL SODIUM) FOR INJECTION, USP CIV For Intravenous Use in Adults For Rectal and Intramuscular Use Only in Pediatric Patients WARNING BREVITAL SHOULD BE USED ONLY IN HOSPITAL OR AMBULATORY CARE SETTINGS THAT PROVIDE FOR CONTINUOUS MONITORING OF RESPIRATORY (E.G. PULSE OXIMETRY) AND CARDIAC FUNCTION. IMMEDIATE AVAILABILITY OF RESUSCITATIVE DRUGS AND AGE- AND SIZE-APPROPRIATE EQUIPMENT FOR BAG/VALVE/MASK VENTILATION AND INTUBATION AND PERSONNEL TRAINED IN THEIR USE AND SKILLED IN AIRWAY MANAGEMENT SHOULD BE ASSURED. FOR DEEPLY SEDATED PATIENTS, A DESIGNATED INDIVIDUAL OTHER THAN THE PRACTITIONER PERFORMING THE PROCEDURE SHOULD BE PRESENT TO CONTINUOUSLY MONITOR THE PATIENT. (SEE WARNINGS.) DESCRIPTION BREVITAL® (methohexital sodium, USP) for injection, is 2,4,6 (1_H_, 3_H_, 5_H_)-Pyrimidinetrione, 1- methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (±)-, monosodium salt and has the empirical formula C H N NaO . Its molecular weight is 284.29. The structural formula is as follows: Methohexital sodium is a rapid, ultrashort-acting barbiturate anesthetic. Methohexital sodium for injection is a freeze-dried, sterile, nonpyrogenic mixture of methohexital sodium with 6% anhydrous sodium carbonate added as a buffer. It contains not less than 90% and not more than 110% of the labeled amount of methohexital sodium. It occurs as a white, freeze-dried plug that is freely soluble in water. This product is oxygen sensitive. The pH of the 1% solution is between 10 and 11; the pH of the 0.2% solution in 5% dextrose is between 9.5 and 10.5. Methohexital sodium may be administered by direct intravenous injection or continuous intravenous drip, intramuscular or rectal routes (see PRECAUTIONS/PEDIATRIC USE). Reconstituting instructions vary depending on the route of administration (see DOSAGE AND ADMINISTRATION). ® 14 17 2 3 CLINICAL PHARMACOLOGY Compared with thiamylal and thiopental, methohexital Lue koko asiakirja